tetano
Editor, Senior Moderator
Haematologica
. 2022 May 12.
doi: 10.3324/haematol.2022.280847. Online ahead of print.
COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)
Francesco Marchesi[SUP] 1 [/SUP], Jon Salmanton-García[SUP] 2 [/SUP], Ziad Emarah[SUP] 3 [/SUP], Klára Piukovics[SUP] 4 [/SUP], Marcio Nucci[SUP] 5 [/SUP], Alberto López-García[SUP] 6 [/SUP], Zdeněk Ráčil[SUP] 7 [/SUP], Francesca Farina[SUP] 8 [/SUP], Marina Popova[SUP] 9 [/SUP], Sofia Zompi[SUP] 10 [/SUP], Ernesta Audisio[SUP] 10 [/SUP], Marie-Pierre Ledoux[SUP] 11 [/SUP], Luisa Verga[SUP] 12 [/SUP], Barbora Weinbergerová[SUP] 13 [/SUP], Tomas Szotkovski[SUP] 14 [/SUP], Maria Gomes Da Silva[SUP] 15 [/SUP], Nicola Fracchiolla[SUP] 16 [/SUP], Nick De Jonge[SUP] 17 [/SUP], Graham Collins[SUP] 18 [/SUP], Monia Marchetti[SUP] 19 [/SUP], Gabriele Magliano[SUP] 20 [/SUP], Carolina García-Vidal[SUP] 21 [/SUP], Monika M Biernat[SUP] 22 [/SUP], Jaap Van Doesum[SUP] 23 [/SUP], Marina Machado[SUP] 24 [/SUP], Fatih Demirkan[SUP] 25 [/SUP], Murtadha Al-Khabori[SUP] 26 [/SUP], Pavel Žák[SUP] 27 [/SUP], Benjamín Víšek[SUP] 27 [/SUP], Igor Stoma[SUP] 28 [/SUP], Gustavo-Adolfo Méndez[SUP] 29 [/SUP], Johan Maertens[SUP] 30 [/SUP], Nina Khanna[SUP] 31 [/SUP], Ildefonso Espigado[SUP] 32 [/SUP], Giulia Dragonetti[SUP] 33 [/SUP], Luana Fianchi[SUP] 33 [/SUP], Maria Ilaria Del Principe[SUP] 34 [/SUP], Alba Cabirta[SUP] 35 [/SUP], Irati Ormazabal-Vélez[SUP] 36 [/SUP], Ozren Jaksic[SUP] 37 [/SUP], Caterina Buquicchio[SUP] 38 [/SUP], Valentina Bonuomo[SUP] 39 [/SUP], Josip Batinić[SUP] 40 [/SUP], Ali S Omrani[SUP] 41 [/SUP], Sylvain Lamure[SUP] 42 [/SUP], Olimpia Finizio[SUP] 43 [/SUP], Noemí Fernández[SUP] 44 [/SUP], Iker Falces-Romero[SUP] 45 [/SUP], Ola Blennow[SUP] 46 [/SUP], Rui Bergantim[SUP] 47 [/SUP], Natasha Ali[SUP] 48 [/SUP], Sein Win[SUP] 49 [/SUP], Jens Van Praet[SUP] 50 [/SUP], Maria Chiara Tisi[SUP] 51 [/SUP], Ayten Shirinova[SUP] 52 [/SUP], Martin Schönlein[SUP] 53 [/SUP], Juergen Prattes[SUP] 54 [/SUP], Monica Piedimonte[SUP] 55 [/SUP], Verena Petzer[SUP] 56 [/SUP], Milan Navrátil[SUP] 57 [/SUP], Austin Kulasekararaj[SUP] 58 [/SUP], Pavel Jindra[SUP] 59 [/SUP], Jiří Sramek[SUP] 60 [/SUP], Andreas Glenthøj[SUP] 61 [/SUP], Rita Fazzi[SUP] 62 [/SUP], Cristina De Ramón-Sánchez[SUP] 63 [/SUP], Chiara Cattaneo[SUP] 64 [/SUP], Maria Calbacho[SUP] 65 [/SUP], Nathan C Bahr[SUP] 66 [/SUP], Shaimaa El-Ashwah[SUP] 3 [/SUP], Raul Cordoba[SUP] 6 [/SUP], Michaela Hanakova[SUP] 67 [/SUP], Giovanni Zambrotta[SUP] 12 [/SUP], Mariarita Sciumè[SUP] 16 [/SUP], Stephen Booth[SUP] 18 [/SUP], Raquel Nunes Rodrigues[SUP] 15 [/SUP], Maria Vittoria Sacchi[SUP] 19 [/SUP], Nicole García-Poutón[SUP] 21 [/SUP], Juan-Alberto Martín-González[SUP] 68 [/SUP], Sofya Khostelidi[SUP] 69 [/SUP], Stefanie Gräfe[SUP] 70 [/SUP], Laman Rahimli[SUP] 71 [/SUP], Emanuele Ammatuna[SUP] 23 [/SUP], Alessandro Busca[SUP] 10 [/SUP], Paolo Corradini[SUP] 72 [/SUP], Martin Hoenigl[SUP] 73 [/SUP], Nikolai Klimko[SUP] 69 [/SUP], Philipp Koehler[SUP] 71 [/SUP], Antonio Pagliuca[SUP] 74 [/SUP], Francesco Passamonti[SUP] 75 [/SUP], Oliver A Cornely[SUP] 76 [/SUP], Livio Pagano[SUP] 77 [/SUP]
Affiliations
Abstract
Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p.
. 2022 May 12.
doi: 10.3324/haematol.2022.280847. Online ahead of print.
COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)
Francesco Marchesi[SUP] 1 [/SUP], Jon Salmanton-García[SUP] 2 [/SUP], Ziad Emarah[SUP] 3 [/SUP], Klára Piukovics[SUP] 4 [/SUP], Marcio Nucci[SUP] 5 [/SUP], Alberto López-García[SUP] 6 [/SUP], Zdeněk Ráčil[SUP] 7 [/SUP], Francesca Farina[SUP] 8 [/SUP], Marina Popova[SUP] 9 [/SUP], Sofia Zompi[SUP] 10 [/SUP], Ernesta Audisio[SUP] 10 [/SUP], Marie-Pierre Ledoux[SUP] 11 [/SUP], Luisa Verga[SUP] 12 [/SUP], Barbora Weinbergerová[SUP] 13 [/SUP], Tomas Szotkovski[SUP] 14 [/SUP], Maria Gomes Da Silva[SUP] 15 [/SUP], Nicola Fracchiolla[SUP] 16 [/SUP], Nick De Jonge[SUP] 17 [/SUP], Graham Collins[SUP] 18 [/SUP], Monia Marchetti[SUP] 19 [/SUP], Gabriele Magliano[SUP] 20 [/SUP], Carolina García-Vidal[SUP] 21 [/SUP], Monika M Biernat[SUP] 22 [/SUP], Jaap Van Doesum[SUP] 23 [/SUP], Marina Machado[SUP] 24 [/SUP], Fatih Demirkan[SUP] 25 [/SUP], Murtadha Al-Khabori[SUP] 26 [/SUP], Pavel Žák[SUP] 27 [/SUP], Benjamín Víšek[SUP] 27 [/SUP], Igor Stoma[SUP] 28 [/SUP], Gustavo-Adolfo Méndez[SUP] 29 [/SUP], Johan Maertens[SUP] 30 [/SUP], Nina Khanna[SUP] 31 [/SUP], Ildefonso Espigado[SUP] 32 [/SUP], Giulia Dragonetti[SUP] 33 [/SUP], Luana Fianchi[SUP] 33 [/SUP], Maria Ilaria Del Principe[SUP] 34 [/SUP], Alba Cabirta[SUP] 35 [/SUP], Irati Ormazabal-Vélez[SUP] 36 [/SUP], Ozren Jaksic[SUP] 37 [/SUP], Caterina Buquicchio[SUP] 38 [/SUP], Valentina Bonuomo[SUP] 39 [/SUP], Josip Batinić[SUP] 40 [/SUP], Ali S Omrani[SUP] 41 [/SUP], Sylvain Lamure[SUP] 42 [/SUP], Olimpia Finizio[SUP] 43 [/SUP], Noemí Fernández[SUP] 44 [/SUP], Iker Falces-Romero[SUP] 45 [/SUP], Ola Blennow[SUP] 46 [/SUP], Rui Bergantim[SUP] 47 [/SUP], Natasha Ali[SUP] 48 [/SUP], Sein Win[SUP] 49 [/SUP], Jens Van Praet[SUP] 50 [/SUP], Maria Chiara Tisi[SUP] 51 [/SUP], Ayten Shirinova[SUP] 52 [/SUP], Martin Schönlein[SUP] 53 [/SUP], Juergen Prattes[SUP] 54 [/SUP], Monica Piedimonte[SUP] 55 [/SUP], Verena Petzer[SUP] 56 [/SUP], Milan Navrátil[SUP] 57 [/SUP], Austin Kulasekararaj[SUP] 58 [/SUP], Pavel Jindra[SUP] 59 [/SUP], Jiří Sramek[SUP] 60 [/SUP], Andreas Glenthøj[SUP] 61 [/SUP], Rita Fazzi[SUP] 62 [/SUP], Cristina De Ramón-Sánchez[SUP] 63 [/SUP], Chiara Cattaneo[SUP] 64 [/SUP], Maria Calbacho[SUP] 65 [/SUP], Nathan C Bahr[SUP] 66 [/SUP], Shaimaa El-Ashwah[SUP] 3 [/SUP], Raul Cordoba[SUP] 6 [/SUP], Michaela Hanakova[SUP] 67 [/SUP], Giovanni Zambrotta[SUP] 12 [/SUP], Mariarita Sciumè[SUP] 16 [/SUP], Stephen Booth[SUP] 18 [/SUP], Raquel Nunes Rodrigues[SUP] 15 [/SUP], Maria Vittoria Sacchi[SUP] 19 [/SUP], Nicole García-Poutón[SUP] 21 [/SUP], Juan-Alberto Martín-González[SUP] 68 [/SUP], Sofya Khostelidi[SUP] 69 [/SUP], Stefanie Gräfe[SUP] 70 [/SUP], Laman Rahimli[SUP] 71 [/SUP], Emanuele Ammatuna[SUP] 23 [/SUP], Alessandro Busca[SUP] 10 [/SUP], Paolo Corradini[SUP] 72 [/SUP], Martin Hoenigl[SUP] 73 [/SUP], Nikolai Klimko[SUP] 69 [/SUP], Philipp Koehler[SUP] 71 [/SUP], Antonio Pagliuca[SUP] 74 [/SUP], Francesco Passamonti[SUP] 75 [/SUP], Oliver A Cornely[SUP] 76 [/SUP], Livio Pagano[SUP] 77 [/SUP]
Affiliations
- PMID: 35545919
- DOI: 10.3324/haematol.2022.280847
Abstract
Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p.